Sixty patients with coronary heart disease, stable angina pectoris of functional class II and III and dislipoproteinemia (cholesterol greater than 6.5 mmol/l, triglycerides greater than 2.0 mmol/l, the atherogenic index greater than 3.5) were assigned to two groups. 40 patients received enterosorbent (high-porous, small-spherical fraction of CKH carbon). 20 control subjects were treated with placebo. The patients age ranged from 60 to 74. The treatment course lasted for 4 weeks. Evaluation of the treatment results showed that total cholesterol dropped by 20%, triglycerides by 27%, apoB by 32%, apoB-containing lipoproteins by 20%; there were positive changes in circulation, clinical status (in 60% of cases), exercise tolerance (by 12%). Control patients did not present any noticeable shifts. Thus, enterosorption proved an effective modality of dyslipoproteinemia correction in coronary patients of advanced age.